Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The adverse effects following lumbar myelography and ventriculography with meglumine iothalamate (Conray Meglumin), meglumine iocarmate (Dimer-X, Bis-Conray) and metrizamide (Amipaque), and after thoracic and cervical myelography and cisternography with metrizamide are reviewed. In addition to the published material information given to Nyegaard & Co. from several hospitals participating in clinical trials with metrizamide is also reported. The frequency of minor adverse effects (headache, nausea, vomiting) seems to be about the same with all the three water-soluble contrast media. Convulsions, either localized to the lower part of the body or generalized, may be a problem with meglumine iothalamate and meglumine iocarmate, while the epileptogenic effect is markedly lower with metrizamide. With a technique directed towards preventing contrast medium of high concentration from passing intracranially, the frequency of serious adverse effects may be kept at a very low level. Late adverse effects (adhesive arachnoiditis) occurring after all other water-soluble contrast media are a very minor problem after metrizamide. Serious complications have not been recorded following ventriculography and cisternography with metrizamide. Metrizamide is considered to be the water-soluble contrast medium best suited for use in the subarachnoid space and cerebral ventricles.
 ...
PMID:Adverse effects of water-soluble contrast media in myelography, cisternography and ventriculography. A review with special reference to metrizamide. 40 Sep 6

Evaluation of 60% solution of Methylglucamine iocarmate (Dimer-X) for ventriculography in animal experiment and clinical cases was reported. The experimental result was compared with that of Conray 60 and Angiografin, which was reported in our previous papers. In seven intraventricular injections of 2.0 ml, administered to 6 dogs, convulsion was observed on three occasions, facial myoclonus on 1 and no symptoms on the remaining three. However, in 7 intraventricular injections of 1.5 ml for 6 dogs, 6 were symptom-free and only residual one showed convulsion. And no dog died in either experiment. No changes were seen in a subsequent ventriculogram one month after the 1st ventriculography with Dimer-X and also no histological changes of the ventricular wall were revealed one month after the first experiment. These experimental results suggested less toxicity of Dimer-X than Conray 60 or Angiografin. Clinically, in 17 neurosurgical patients, ventriculography was performed with 1-5 ml of Dimer-X. No patients showed convulsive complication, but there was one episode of vomiting in each of 2 cases and slight headache in one case. From our experimental and clinical studies, it is concluded that the Dimer-X is to be considered the best watersoluble contrast medium for ventriculography at present.
 ...
PMID:[Ventriculography with methylglucamine iocarmate (Dimer-X). Experimental and Clinical study (author's transl)]. 108 58

In an attempt to study the use and value in ventriculography of meglumine iocarmate (Dimer-X), previously accepted as a water soluble contrast medium safe for myelography, we have conducted animal experiments to compare Dimer-X with megulumine iothalamate (Conray 60) and meglumine diatrizoate (Angiografin). We also made clinical studies of Dimer-X. In the animal experiments, 1.5 ml and 2.0 ml of Dimer-X were injected into the ventricles of 7 dogs. We noted the apparent superiority of Dimer-X over Conray 60 and Angiografin as far as side effects were concerned, but there were no particular differences in the intensities of the ventriculograms obtained. Morphological studies of the ventricles and histological examinations of the ventricular walls 1 month after intraventricular injections of Dimer-X showed no abnormalities. In the clinical studies, ventriculography with 1-5 ml Dimer-X, performed on 17 cases, aged 8 months to 62 years, with diseases of the central nervous system, produced ventriculograms of good diagnostic value with no side effects, such as convulsions, apart from mild headache or vomiting in 4 instances.
 ...
PMID:Ventriculography with methylglucamine iocarmate (Dimer-X). Experimental and clinical study. 108 93

We compared Hexabrix 320 (580 mOsm kg-1) with Conray 420 (2500 mOsm kg-1) for left ventriculography using a prospective randomised double-blind protocol. One hundred consecutive patients with suspected coronary disease were assigned to Hexabrix (52) or Conray (48) for left ventriculography (dose 10 ml m-2 BSA; flow rate 12 ml s-1). Thirteen patients found Hexabrix unpleasant compared with 24 receiving Conray; overall the feelings of warmth and discomfort were less with Hexabrix than Conray (p less than 0.01 and p less than 0.02 respectively). The incidence of nausea, vomiting, and hypersensitivity was similar. Angiographic quality was better with Conray than with Hexabrix (p less than 0.05). Average changes in heart rate and systolic pressure were similar, though there was greater variation in systolic pressure change after Conray (p less than 0.025). End diastolic pressure increased more after Conray than after Hexabrix (p less than 0.05). These slight advantages of Hexabrix over Conray may be valuable in patients requiring multiple angiograms or in those with impaired cardiac function, but do not justify its use for routine angiography.
 ...
PMID:Comparison of Hexabrix 320 and Conray 420 for left ventriculography in patients with coronary artery disease. 636 33

Spontaneous ventriculocisternostomy rarely occurs in obstructive hydrocephalus. The authors experienced a case of spontaneous ventriculocisternostomy diagnosed by CT scan with metrizamide and Conray. Patient was 23-year-old male who had been in good health until one month before admission, when he began to have headache and tinnitus. He noticed bilateral visual acuity was decreased about one week before admission and vomiting appeared two days before admission. He was admitted to our hospital because of bilateral papilledema and remarkable hydrocephalus diagnosed by CT scan. On admission, no abnormal neurological signs except for bilateral papilledema were noted. Immediately, right ventricular drainage was performed. Pressure of the ventricle was over 300 mmH2O and CSF was clear. PVG and PEG disclosed an another cavity behind the third ventricle, which was communicated with the third ventricle, and occlusion of aqueduct of Sylvius. Metrizamide CT scan and Conray CT scan showed a communication between this cavity and quadrigeminal and supracerebellar cisterns. On these neuroradiological findings, the diagnosis of obstructive hydrocephalus due to benign aqueduct stenosis accompanied with spontaneous ventriculocisternostomy was obtained. Spontaneous ventriculocisternostomy was noticed to produce arrest of hydrocephalus, but with our case, spontaneous regression of such symptoms did not appeared. In the literature, arrest of hydrocephalus was noted in 50 per cent of 14 cases of obstructive hydrocephalus with spontaneous ventriculocisternostomy. By surgical ventriculocisternostomy (method by Torkildsen, Dandy, or Scarff), arrest of hydrocephalus was seen in about 50 to 70 per cent, which was the same results as those of spontaneous ventriculocisternostomy. It is concluded that VP shunt or VA shunt is thought to be better treatment of obstructive hydrocephalus than the various kinds of surgical ventriculocisternostomy.
 ...
PMID:[Case of spontaneous ventriculocisternostomy: with special reference to a CT finding]. 660 89